Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04560166
Title Naxitamab and GM-CSF in Combination With IT in Patients With High-Risk Neuroblastoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Y-mAbs Therapeutics
Indications

neuroblastoma

Therapies

Irinotecan + Naxitamab + Sargramostim + Temozolomide

Age Groups: adult | senior | child
Covered Countries


No variant requirements are available.